Oncologist uptake of comprehensive genomic profile guided targeted therapy.
clinical decision making
comprehensive genomic profiling
next-generation sequencing
real world data
targeted therapy
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
23 Jul 2019
23 Jul 2019
Historique:
received:
19
03
2019
accepted:
19
06
2019
entrez:
7
8
2019
pubmed:
7
8
2019
medline:
7
8
2019
Statut:
epublish
Résumé
We describe the extent to which comprehensive genomic profiling (CGP) results were used by oncologists to guide targeted therapy selection in a cohort of solid tumor patients tested as part of standard care at Roswell Park Comprehensive Cancer Center June 2016-June 2017, with adequate follow up through September 2018 (
Identifiants
pubmed: 31384390
doi: 10.18632/oncotarget.27047
pii: 27047
pmc: PMC6659802
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4616-4629Subventions
Organisme : NCI NIH HHS
ID : P30 CA016056
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233191
Pays : United States
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST Disclosures: MKN, PDP, APS, JMC, FLL, STG, MG, and CM are all employees of OmniSeq, Inc. (Buffalo, NY, USA) and hold restricted stock in OmniSeq, Inc. GKD, AE, HC, AGM, PB, MSE, IP, SE, SA, MO, GC, KO, PF, and SL are employees of Roswell Park Comprehensive Cancer Center (Buffalo, NY, USA). Roswell Park Comprehensive Cancer Center is the majority shareholder of OmniSeq, Inc. MSE provides remunerated consulting to OmniSeq, Inc.
Références
Oncologist. 2010;15(4):390-404
pubmed: 20350999
J Clin Oncol. 2011 May 20;29(15):2046-51
pubmed: 21483012
J Transl Med. 2012 Jul 09;10:85
pubmed: 22554099
Clin Cancer Res. 2012 Nov 15;18(22):6373-83
pubmed: 22966018
Genet Med. 2013 Jul;15(7):565-74
pubmed: 23788249
Nat Biotechnol. 2013 Nov;31(11):1023-31
pubmed: 24142049
Neoplasia. 2015 Apr;17(4):385-99
pubmed: 25925381
Oncotarget. 2015 Aug 21;6(24):20099-110
pubmed: 26015395
J Clin Oncol. 2015 Sep 1;33(25):2815-20
pubmed: 26195710
Oncologist. 2015 Sep;20(9):1011-8
pubmed: 26205736
J Clin Oncol. 2015 Nov 10;33(32):3817-25
pubmed: 26304871
J Natl Cancer Inst. 2015 Sep 15;107(11):
pubmed: 26378224
J Thorac Oncol. 2015 Nov;10(11):1648-52
pubmed: 26536196
J Natl Cancer Inst. 2015 Dec 29;108(2):null
pubmed: 26714555
JAMA Oncol. 2016 Nov 1;2(11):1452-1459
pubmed: 27273579
Oncotarget. 2016 Aug 30;7(35):56491-56500
pubmed: 27447854
Genome Med. 2016 Oct 25;8(1):109
pubmed: 27782854
J Mol Diagn. 2017 Mar;19(2):313-327
pubmed: 28188106
Cancer Discov. 2017 Jun;7(6):596-609
pubmed: 28336552
Oncotarget. 2017 Jun 27;8(26):41806-41814
pubmed: 28415679
Oncotarget. 2017 Apr 18;8(16):27145-27154
pubmed: 28423702
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
BMC Cancer. 2017 Aug 30;17(1):602
pubmed: 28854908
Ann Oncol. 2017 Sep 1;28(9):2298-2304
pubmed: 28911072
Oncotarget. 2017 Jun 14;8(34):57845-57854
pubmed: 28915716
Sci Rep. 2017 Oct 2;7(1):12510
pubmed: 28970558
Oncologist. 2017 Dec;22(12):1444-1450
pubmed: 29079636
JCO Precis Oncol. 2017;2017:null
pubmed: 29082359
Oncologist. 2018 Jul;23(7):776-781
pubmed: 29540602
Oncotarget. 2018 Apr 17;9(29):20282-20293
pubmed: 29755651
JCO Precis Oncol. 2017;2017:null
pubmed: 30003184
J Clin Oncol. 2019 Jun 10;37(17):1460-1469
pubmed: 30892987
J Clin Oncol. 2019 Jun 1;37(16):1370-1379
pubmed: 30892989